Open Accessibility Menu

Clinical Trial Information

A Phase II, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy

Study Details

This study is evaluating a new drug for the treatment of IgA Nephropathy

Primary Sponsor:

MD Serono Research & Development Institute, Inc. (US)

Prinicipal Investigator:

Dr. Scott Cohen/Nephrology

Contact Phone:

(202) 741-3047
A Phase II, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy lwitkin@mfa.gwu.edu

Interested in More Information

  • Please enter your first name.
  • Please enter your last name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
    Please enter your phone number.
    You entered an invalid number.
  • Please enter your address.
  • Please enter your city.
  • Please enter your state.
  • Please enter your zip code.
  • (All Uppercase. No Spaces)